Τρίτη, 10 Νοεμβρίου, 2026
15.7 C
Rhodes

Lavipharm: Investments and acquisitions drive growth and international expansion

Lavipharm Group recorded a 24.1% increase in consolidated sales before clawbacks and rebates, while EBITDA from continuing operations rose by 5.2% in the first half of 2026. The results confirm… Lavipharm: Investments and acquisitions drive growth…

- Advertisement -spot_img

Διαβάστε Επίσης

- Advertisement -spot_img

Περισσότερα

- Advertisement -spot_img

Πρόσφατες Ειδήσεις

- Advertisement -spot_img
- Advertisement -spot_img